Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRx-4DP0004 in Asthma
NCT03851250Phase 1Terminated
- Sponsor
- 4D Pharma plc
- Start
- Jul 2019
- Primary completion
- Apr 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in asthma comparing MRx-4DP0004 with Placebo (2 arms). Primary endpoints: Number of participants experiencing adverse events at Day 127 and Clinically relevant adverse changes in clinical laboratory tests at Day 127. Started Jul 2019; status: terminated.
02
Drugs
MRx-4DP0004
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03851250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03851250.